LTZ Therapeutics, a clinical-stage, immunotherapy-focused biotechnology company, today announced that the U.S. Food and Drug ...

A UCLA study has identified a hidden Achilles' heel in aggressive small cell cancers that have resisted new treatments for ...

The development of cancer is not a process triggered immediately by the emergence of an oncogenic mutation. There is growing ...

(NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune ...

FDA cleared Tregzi to improve chronic GVHD-free survival, representing a non-pharmacologic strategy to reduce chronic GVHD while supporting immune reconstitution after allogeneic transplantation.

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of ...

First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics ProfileAI Aided Target Engagement Research Advancing Development of ...

The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP ...

Tampa’s emergence reflects a broader shift in the advancement of cancer care. This microscope image, made available by the National Cancer Institute Center for Cancer Research, shows human colon ...

India, June 10 -- Artificial intelligence company Anthropic has introduced Claude Fable 5, a new AI system that the company describes as the first public release from its powerful Mythos class of ...

Johnson & Johnson announced Monday it has entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash, betting that an emerging class of antibody-linked protein degraders ...